patents.google.com

MX354828B - Monovalent metal cation dry powders for inhalation. - Google Patents

  • ️Thu Mar 22 2018

MX354828B - Monovalent metal cation dry powders for inhalation. - Google Patents

Monovalent metal cation dry powders for inhalation.

Info

Publication number
MX354828B
MX354828B MX2013003478A MX2013003478A MX354828B MX 354828 B MX354828 B MX 354828B MX 2013003478 A MX2013003478 A MX 2013003478A MX 2013003478 A MX2013003478 A MX 2013003478A MX 354828 B MX354828 B MX 354828B Authority
MX
Mexico
Prior art keywords
dry powders
monovalent metal
inhalation
metal cation
cation dry
Prior art date
2010-09-29
Application number
MX2013003478A
Other languages
Spanish (es)
Other versions
MX2013003478A (en
Inventor
Michael M Lipp
Jean C Sung
Original Assignee
Pulmatrix Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
2010-09-29
Filing date
2011-09-29
Publication date
2018-03-22
2011-08-26 Priority claimed from PCT/US2011/049435 external-priority patent/WO2012030664A1/en
2011-09-29 Application filed by Pulmatrix Operating Co Inc filed Critical Pulmatrix Operating Co Inc
2013-10-30 Publication of MX2013003478A publication Critical patent/MX2013003478A/en
2018-03-22 Publication of MX354828B publication Critical patent/MX354828B/en

Links

  • 239000000843 powder Substances 0.000 title abstract 3
  • 150000001768 cations Chemical class 0.000 title abstract 2
  • 239000002184 metal Substances 0.000 title abstract 2
  • -1 Na+) Chemical class 0.000 abstract 1
  • 239000013543 active substance Substances 0.000 abstract 1
  • 239000002245 particle Substances 0.000 abstract 1
  • 210000002345 respiratory system Anatomy 0.000 abstract 1
  • 238000012385 systemic delivery Methods 0.000 abstract 1
  • 238000012384 transportation and delivery Methods 0.000 abstract 1

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)

Abstract

The present invention is directed toward respirable dry powders and particles for systemic delivery of pharmaceutically active agents or delivery to the respiratory tract. The dry powders contain one or more monovalent metal cations (such as Na+), are small and dispersible.

MX2013003478A 2010-09-29 2011-09-29 Monovalent metal cation dry powders for inhalation. MX354828B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38788310P 2010-09-29 2010-09-29
US201161481879P 2011-05-03 2011-05-03
PCT/US2011/049435 WO2012030664A1 (en) 2010-08-30 2011-08-26 Dry powder formulations and methods for treating pulmonary diseases
PCT/US2011/053829 WO2012044736A1 (en) 2010-09-29 2011-09-29 Monovalent metal cation dry powders for inhalation

Publications (2)

Publication Number Publication Date
MX2013003478A MX2013003478A (en) 2013-10-30
MX354828B true MX354828B (en) 2018-03-22

Family

ID=45002202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013003478A MX354828B (en) 2010-09-29 2011-09-29 Monovalent metal cation dry powders for inhalation.

Country Status (12)

Country Link
US (6) US9642798B2 (en)
EP (2) EP4008326A1 (en)
JP (3) JP5877204B2 (en)
KR (2) KR101915241B1 (en)
CN (2) CN107096014B (en)
AU (2) AU2011308865B2 (en)
BR (1) BR112013007304B1 (en)
CA (2) CA3086367A1 (en)
IL (4) IL286573B (en)
MX (1) MX354828B (en)
RU (2) RU2640921C2 (en)
WO (1) WO2012044736A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE112008001301T5 (en) 2007-05-14 2010-04-29 Reserach Foundation Of State University Of New York Induction of a physiological dispersion response in bacterial cells in a biofilm
MX354828B (en) * 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Monovalent metal cation dry powders for inhalation.
WO2013130767A1 (en) * 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
GB201215988D0 (en) * 2012-09-07 2012-10-24 Reckitt Benckiser Healthcare Int Ltd Pharmaceutical compositions comprising flurbiprofen
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
WO2016057644A1 (en) * 2014-10-08 2016-04-14 Pulmatrix Operating Company, Inc. Improved stability of dry powders containing tiotropium and amino acid
US20170304197A1 (en) * 2014-10-08 2017-10-26 Pulmatrix Operating Company, Inc. Formulations containing tiotropium, amino acid and acid and methods thereof
AU2015338717B2 (en) 2014-10-31 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Powder formulation
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
PT108885B (en) 2015-10-12 2019-02-13 Hovione Farm S A METHOD OF PRODUCTION OF INHALABLE COMPOSITE PARTICULARS USING A THREE FLUID ATOMIZER
EP3407870B1 (en) * 2016-01-29 2022-06-29 MannKind Corporation Dry powder inhaler
CN106116561B (en) * 2016-06-28 2018-10-12 南通众兴磁业有限公司 Permanent-magnet ferrite magnetic material
CA3040828A1 (en) 2016-10-31 2018-05-03 Vectura Limited Inhalable powder composition comprising il-13 antibody
EP3760189A4 (en) * 2018-02-26 2022-01-05 Shin Nippon Biomedical Laboratories, Ltd. PULVERULENT PREPARATION, CARTRIDGE AND DEVICE
PT3833964T (en) * 2018-08-07 2023-08-17 Norton Waterford Ltd Application of raman spectroscopy for the manufacture of inhalation powders
CN110161142A (en) * 2019-06-11 2019-08-23 珠海瑞思普利生物制药有限公司 A kind of characterization dry powder inhaler formulations are in the aerodynamic simulator of respiratory system
WO2021012044A1 (en) 2019-07-22 2021-01-28 Canopy Growth Corporation Continuous crystallization of cannabinoids in a stirred-tank reactor
WO2021202429A1 (en) * 2020-03-28 2021-10-07 Esrail Medical Corp. Methods and compositions for treatment of covid-19
WO2022073459A1 (en) * 2020-10-09 2022-04-14 刘志 Inhalation formulation, and preparation method therefor and application thereof
US20220151920A1 (en) * 2020-11-18 2022-05-19 Bend Research, Inc. Inhalable dry powder formulations comprising angiogenesis inhibitors
AU2022476747A1 (en) * 2022-09-02 2025-02-06 Liita Care Aps Pharmaceutical dry powder composition and methods for treating respiratory tract infections

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1575050A1 (en) 1966-01-12 1972-04-13 Misto Gen Equipment Co Ultrasonic fog generator
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US4085893A (en) 1974-03-20 1978-04-25 Durley Iii Benton A Ultrasonic humidifiers, atomizers and the like
US4193009A (en) 1976-01-26 1980-03-11 Durley Benton A Iii Ultrasonic piezoelectric transducer using a rubber mounting
JPS5550437U (en) 1978-09-28 1980-04-02
US4233405A (en) 1979-10-10 1980-11-11 Rohm And Haas Company Process for spray drying enzymes
DE3229179C2 (en) 1982-08-05 1986-04-17 A. Nattermann & Cie GmbH, 5000 Köln Pulmonary surfactant
US4643351A (en) 1984-06-14 1987-02-17 Tokyo Sanyo Electric Co. Ultrasonic humidifier
US4637815A (en) 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
FI82808C (en) 1987-12-31 1991-04-25 Etelae Haemeen Keuhkovammayhdi Ultraljudfinfördelningsanordning
US5511726A (en) 1988-09-23 1996-04-30 Battelle Memorial Institute Nebulizer device
US4899914A (en) 1988-11-04 1990-02-13 Ciba-Geigy Corporation Method for producing a sterile preservative-free aerosol saline solution
US4921639A (en) 1988-11-09 1990-05-01 Bernard Chiu Ultrasonic humidifier
US4881541A (en) 1988-12-21 1989-11-21 The Regents Of The University Of California Vaporizer for an anesthetic having a vapor pressure about one atmosphere
IT1228459B (en) 1989-02-23 1991-06-19 Phidea S R L INHALER WITH REGULAR AND COMPLETE EMPTYING OF THE CAPSULE.
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5175152A (en) 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
US5211944A (en) 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
US5571535A (en) 1990-11-30 1996-11-05 Flowers; Marianne Treatment of topical infections
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
DK0592540T3 (en) 1991-07-02 2000-06-26 Inhale Inc Method and apparatus for dispensing aerosolized drugs
JPH05123398A (en) 1991-11-06 1993-05-21 Tsunemasa Kamiyama Throat protection inhalation agent and inhalation instrument
GB2265845B (en) 1991-11-12 1996-05-01 Medix Ltd A nebuliser and nebuliser control system
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3961029B2 (en) 1992-06-24 2007-08-15 博 木戸 Influenza virus infection inhibitor
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5292127C1 (en) * 1992-10-02 2001-05-22 Arcade Planet Inc Arcade game
US5898037A (en) 1992-11-13 1999-04-27 Marx; Alvin J. Formulations of magnesium compounds for local application and methods of treatment using the same
US5724957A (en) 1993-01-29 1998-03-10 Aradigm Corporation Intrapulmonary delivery of narcotics
US6098620A (en) 1993-01-29 2000-08-08 Aradigm Corporation Device for aerosolizing narcotics
US5709202A (en) 1993-05-21 1998-01-20 Aradigm Corporation Intrapulmonary delivery of aerosolized formulations
NZ328476A (en) 1993-06-24 1999-05-28 Astra Ab Use of a two component insulin preparation in an inhalation device
US5514665A (en) 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
AUPM411494A0 (en) 1994-02-25 1994-03-24 Central Sydney Area Health Service Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum
US5633003A (en) 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
JP3414539B2 (en) 1994-05-11 2003-06-09 有限会社ドット Composition for nasal absorption
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
MX9702670A (en) 1994-10-14 1997-07-31 Yamanouchi Pharma Co Ltd Azole derivative.
US5863563A (en) 1994-10-20 1999-01-26 Alphagene Inc. Treatment of pulmonary conditions associated with insufficient secretion of surfactant
US5747002A (en) 1995-04-05 1998-05-05 Genentech, Inc. Preparation of sodium chloride aerosol formulations
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
RO119117B1 (en) 1995-04-14 2004-04-30 Glaxo Wellcome Inc. FIXED DOSE INHALATOR FOR PROPIONED FLUTICAZONE
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US20050054682A1 (en) 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
GB9606677D0 (en) 1996-03-29 1996-06-05 Glaxo Wellcome Inc Process and device
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
RU2140273C1 (en) * 1996-11-06 1999-10-27 Закрытое акционерное общество "АЭРОМЕД" Method of treatment of patients with catarrhal illnesses
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
DE19653969A1 (en) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for the production of propellant-free aerosols
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5881720A (en) * 1997-04-29 1999-03-16 The Procter & Gamble Company Method of delivering halotherapy
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6339075B1 (en) 1997-06-30 2002-01-15 The University Of British Columbia Use of dextran and other polysaccharides to improve mucus clearance
JP4526702B2 (en) 1997-09-29 2010-08-18 ネクター セラピューティックス Stabilized bioactive formulations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
EA003328B1 (en) 1998-04-08 2003-04-24 Эли Лилли Энд Компани Pulmonary and nasal delivery of raloxifene
US5883084A (en) 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
SE9802073D0 (en) 1998-06-11 1998-06-11 Astra Ab New use
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
FR2780285B1 (en) 1998-06-29 2001-10-05 Goemar Lab Sa USE OF ISOOSMOTIC SALINE SOLUTIONS, THEIR PREPARATION METHOD AND ANTI-INFLAMMATORY DRUGS BASED ON SUCH SOLUTIONS
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
GB9827145D0 (en) 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
JP3312216B2 (en) 1998-12-18 2002-08-05 オムロン株式会社 Spraying equipment
US6926911B1 (en) 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
AU4979700A (en) 1999-05-03 2000-11-17 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
WO2001013892A2 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) * 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
DE60025019T2 (en) 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSIBILITY
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
AU772096B2 (en) 2000-03-14 2004-04-08 Sumika Enviro-Science Co., Ltd. Method for denaturing allergens
SK284948B6 (en) 2000-04-06 2006-03-02 Zentiva, A. S. Pharmaceutical composition with a content of calcium or mixture of calcium and vitamin D or mixture of calcium and magnesium in a new formulation
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (en) 2000-04-17 2002-01-07 Chiesi Farma Spa PHARMACEUTICAL FORMULATIONS FOR DRY POWDER INHALERS IN THE FORM OF HARD AGGLOMERATES
US6637432B2 (en) 2000-05-09 2003-10-28 Iep Pharmaceutical Devices Inc. Inhalation actuated device
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1913939T3 (en) 2000-06-27 2017-09-18 Vectura Ltd Formulations for use in inhalers
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US6669959B1 (en) 2000-07-18 2003-12-30 Aeropharm Technology Incorporated Modulated release particles for lung delivery
AU2001278131A1 (en) 2000-08-01 2002-02-13 Shofner Engineering Associates, Inc. Generation, delivery, measurement and control of aerosol boli for diagnostics and treatments of the respiratory/pulmonary tract of a patient
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP1328214A4 (en) 2000-09-20 2009-07-29 Shahinian Lee Jr Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
US20040081627A1 (en) 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
EP2298285A3 (en) 2000-11-30 2011-07-27 Vectura Limited Method of making particles for use in a pharmaceutical composition
PT2301524E (en) 2000-12-27 2013-07-10 Gilead Sciences Inc Inhalable aztreonam without arginine for treatment and prevention of pulmonary bacterial infections
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
AU2002240137A1 (en) 2001-01-30 2002-08-12 University Of Iowa Research Foundation Antiviral activities of primate theta defensins and mammalian cathelicidins
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6511050B2 (en) 2001-05-02 2003-01-28 Dynamo Aviation, Inc. Humidifier
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
JP2003074919A (en) 2001-08-31 2003-03-12 Sunbow Precision Co Ltd Composite humidifier
US20050123509A1 (en) * 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20030203930A1 (en) 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
BR0214438A (en) 2001-11-26 2004-11-03 Daiichi Suntory Pharma Co Ltd Pharmaceutical composition for nasal absorption
US6851626B2 (en) 2002-01-07 2005-02-08 Aerogen, Inc. Methods and devices for nebulizing fluids
GB2384198B (en) 2002-01-18 2005-03-02 Profile Drug Delivery Ltd Nebulizer metering
GB0217199D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20030232019A1 (en) 2002-02-22 2003-12-18 Advanced Inhalation Research, Inc. Inhalable formulations for sustained release
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
ES2609482T3 (en) 2002-03-20 2017-04-20 Civitas Therapeutics, Inc. Lung administration of levodopa
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
GB0209783D0 (en) 2002-04-29 2002-06-05 Glaxo Group Ltd Medicament dispenser
US20050220720A1 (en) 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
WO2003094900A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
JP4533134B2 (en) 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド Nanoparticulate policosanol formulations and novel policosanol combinations
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
WO2004002551A2 (en) * 2002-06-28 2004-01-08 Advanced Inhalation Research, Inc. Inhalable epinephrine
US6916001B2 (en) * 2002-07-10 2005-07-12 Lowell Thomas Pugh, Jr. Concrete form apparatus and method for assembly thereof
GB0217198D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7371729B2 (en) 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
EP1556018A1 (en) 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
CN101804200A (en) 2002-11-22 2010-08-18 余芒 Broad spectrum anti-viral therapeutics and prophylaxis
US7534781B2 (en) 2003-03-21 2009-05-19 Dsm Ip Assets B.V. Crystalline amoxicillin trihydrate powder
CN1194062C (en) 2003-04-04 2005-03-23 王泽斌 Combination of snow melt and melting ice as well as its preparation method and application
CA2523740C (en) 2003-05-01 2012-05-15 Innogene Kalbiotech Pte Ltd Lactate containing pharmaceutical composition and uses thereof
WO2004103478A1 (en) 2003-05-20 2004-12-02 Collins James F Ophthalmic drug delivery system
US7195179B2 (en) 2003-06-01 2007-03-27 Piezo Technologies Piezoelectric mist generation device
JP2009514779A (en) 2003-07-11 2009-04-09 グラクソ グループ リミテッド Pharmaceutical formulation
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0324897D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
KR20050056622A (en) 2003-12-10 2005-06-16 주식회사 대우일렉트로닉스 Flash rom download apparatus
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
EP1713441A2 (en) 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20050207983A1 (en) 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
SE528121C2 (en) 2004-03-29 2006-09-05 Mederio Ag Preparation of dry powder for pre-measured DPI
EP1734962A4 (en) 2004-03-30 2010-07-14 Painceptor Pharma Corp Compositions and methods for modulating gated ion channels
CA2602596A1 (en) 2004-03-30 2005-10-13 Malcolm King Compositions and methods for improved mucus function
US20050281740A1 (en) 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
AU2005259501A1 (en) 2004-06-29 2006-01-12 Jado Technologies Gmbh Sphingolipids against pathological processes in lipid rafts
DE102004031863B3 (en) 2004-07-01 2006-03-09 Airbus Deutschland Gmbh Device for fixing in particular planar workpieces with a contact surface
CN101090714A (en) 2004-07-26 2007-12-19 康泽里克斯公司 Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1796677A4 (en) 2004-09-07 2009-07-08 Smithkline Beecham Corp Method for activating trpv4 channel receptors by agonists
US20060073173A1 (en) 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US8627821B2 (en) 2005-01-10 2014-01-14 Pulmatrix, Inc. Method and device for decreasing contamination
WO2006084131A2 (en) 2005-02-01 2006-08-10 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furin inhibitors and alpha-defensins for the treatment or prevention of papillomavirus infection
WO2006086704A2 (en) 2005-02-10 2006-08-17 Borgwarner Inc. Power flow configuration for dual clutch transmission mechanism
WO2006102438A2 (en) 2005-03-23 2006-09-28 Ihc Intellectual Asset Management, Llc Methods and compositions for irrigation of mucosal tissues
US20060229366A1 (en) 2005-04-07 2006-10-12 Lifschitz Carlos H Method for preventing or treating respiratory infections in infants
AU2006244478B2 (en) 2005-05-05 2012-09-13 Pulmatrix Inc. Ultrasonic aerosol generator
BRPI0609924A2 (en) 2005-05-18 2010-05-11 Pulmatrix Inc use of an aerosol formulation containing about 0.5 to 20% (w / w) of a salt selected from the group consisting of a magnesium salt, a calcium salt, an aluminum salt, a silicon salt, a salt scandium, a titanium salt, a vanadium salt, a chrome salt, a cobalt salt, a nickel salt, a copper salt, a manganese salt, a zinc salt, a tin salt, and a combination thereof, and pharmaceutical composition
CA2608273C (en) * 2005-05-18 2015-10-20 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
ITMI20051999A1 (en) * 2005-10-21 2007-04-22 Eratech S R L INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY
US7575882B2 (en) 2005-10-31 2009-08-18 Janssen Pharmaceutica N. V. Compositions and methods for identifying modulators of TRPV2
GB0523576D0 (en) * 2005-11-18 2005-12-28 Theradeas Ltd Drug composition and its use in therapy
US20070202051A1 (en) 2006-02-10 2007-08-30 Pari Gmbh Aerosols for sinunasal drug delivery
JP2009531445A (en) 2006-03-29 2009-09-03 アレイ バイオファーマ、インコーポレイテッド p38 inhibitors and methods of use thereof
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080063722A1 (en) 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
EP2101748B9 (en) 2006-11-29 2015-02-25 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Use of incensole and derivatives thereof for neuroprotection and for the treatment of depression and anxiety
US8501255B2 (en) 2006-12-14 2013-08-06 Purac Biochem B.V. Particulate composition comprising calcium lactate and calcium citrate microparticles
GB0625322D0 (en) 2006-12-19 2007-01-24 Pharmakodex Ltd Pharmaceutical compositions
EP2011495A1 (en) 2007-07-03 2009-01-07 Sygnis Bioscience GmbH & Co. KG Use of piperine and derivatives thereof for the therapy of neurological conditions
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
GB0719518D0 (en) 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
EP2050437A1 (en) * 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
AU2008333226B2 (en) 2007-12-05 2013-02-07 Janssen Pharmaceutica Nv Dibenzoazepine and dibenzooxazepine TRPA1 agonists
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
NO2252275T3 (en) 2008-02-13 2018-04-28
EP2098219A1 (en) 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
AU2009246217B2 (en) 2008-05-15 2013-01-10 Novartis Ag Pulmonary delivery of a fluoroquinolone
WO2010015965A2 (en) 2008-08-04 2010-02-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for treating neuronal damage and modulating transient receptor potential channels
GB0818476D0 (en) 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
EP2410986A2 (en) 2009-03-26 2012-02-01 Pulmatrix, Inc. Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
CA2754670A1 (en) 2009-03-26 2010-09-30 Pulmatrix, Inc. Anti-influenza formulations and methods
US20120064126A1 (en) * 2009-03-26 2012-03-15 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120058198A1 (en) 2009-03-26 2012-03-08 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
CN102448440A (en) 2009-03-26 2012-05-09 普马特里克斯公司 Pharmaceutical formulations and methods for treating respiratory tract infections
WO2011006073A1 (en) 2009-07-10 2011-01-13 President And Fellows Of Harvard College Permanently charged sodium and calcium channel blockers as anti-inflammatory agents
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
AU2011296343B2 (en) * 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2448571B1 (en) * 2010-08-30 2013-06-12 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
MX354828B (en) * 2010-09-29 2018-03-22 Pulmatrix Operating Co Inc Monovalent metal cation dry powders for inhalation.
PT106094A (en) 2012-01-13 2013-07-15 Hovione Farmaciencia S A ADMINISTRATION BY INHALATION OF FORMULATIONS WITH HIGH DOSE
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
WO2013130767A1 (en) * 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
AU2017341815B2 (en) * 2016-10-14 2023-06-15 Pulmatrix Operating Company, Inc. Antifungal dry powders

Also Published As

Publication number Publication date
CN107096014A (en) 2017-08-29
US20150231066A1 (en) 2015-08-20
AU2011308865B2 (en) 2017-01-05
CA2812414A1 (en) 2012-04-05
IL286573B (en) 2022-08-01
IL256360B (en) 2020-03-31
AU2011308865A1 (en) 2013-04-18
KR20130098370A (en) 2013-09-04
US20190388342A1 (en) 2019-12-26
CN103228273A (en) 2013-07-31
IL256360A (en) 2018-02-28
EP4008326A1 (en) 2022-06-08
AU2016269398A1 (en) 2016-12-22
RU2013118453A (en) 2014-11-10
RU2640921C2 (en) 2018-01-12
US20210121399A1 (en) 2021-04-29
RU2017144619A (en) 2019-02-20
RU2017144619A3 (en) 2021-06-02
BR112013007304B1 (en) 2021-12-14
US20130266653A1 (en) 2013-10-10
US10376465B2 (en) 2019-08-13
KR101915241B1 (en) 2018-11-06
CA3086367A1 (en) 2012-04-05
IL225398A0 (en) 2013-06-27
JP2013540123A (en) 2013-10-31
KR20180122475A (en) 2018-11-12
US20240156728A1 (en) 2024-05-16
JP5877204B2 (en) 2016-03-02
JP6186458B2 (en) 2017-08-23
MX2013003478A (en) 2013-10-30
EP2621484A1 (en) 2013-08-07
US9642798B2 (en) 2017-05-09
WO2012044736A1 (en) 2012-04-05
CN103228273B (en) 2017-04-05
AU2016269398B2 (en) 2018-10-04
JP2017190353A (en) 2017-10-19
BR112013007304A2 (en) 2016-07-05
US11173115B2 (en) 2021-11-16
US20170143624A1 (en) 2017-05-25
JP6392422B2 (en) 2018-09-19
IL225398A (en) 2017-12-31
IL271976A (en) 2020-02-27
CN107096014B (en) 2022-07-15
CA2812414C (en) 2020-09-22
JP2016065107A (en) 2016-04-28
IL286573A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
MX354828B (en) 2018-03-22 Monovalent metal cation dry powders for inhalation.
PH12013502608A1 (en) 2020-10-19 Inhalable pharmaceutical compositions
WO2010111680A3 (en) 2011-02-03 Dry powder formulations and methods for treating pulmonary diseases
TN2015000395A1 (en) 2017-01-03 Respirable agglomerates of porous carrier particles and micronized drug
PH12015500684A1 (en) 2015-05-18 An inhaler
MY179703A (en) 2020-11-11 Dry powder formulation comprising a phosphodiesterase inhibitor
MX2014010147A (en) 2015-10-22 Nasal delivery devices.
EA201291306A1 (en) 2013-05-30 COMPOSITION OF DRY POWDER CONTAINING ANTIMUSCARINE MEANS
WO2012031603A3 (en) 2012-08-16 Airway administration of angiogenesis inhibitors
PL2670395T3 (en) 2015-08-31 Dry powder formulations of particles that contain two or more active ingredients for treating obstructive or inflammatory airways diseases
TR201900670T4 (en) 2019-02-21 Method and formulation for inhalation.
MX2015005768A (en) 2015-11-25 Ultra low density pulmonary powders.
MX2015013845A (en) 2016-05-09 Tiotropium dry powders.
EA201490991A1 (en) 2014-09-30 COMPOSITIONS, METHODS AND DEVICES FOR RESPIRATORY DELIVERY TWO OR MORE ACTIVE MEANS
MX2015012397A (en) 2016-07-26 Composition and methods based on neutralizing antibodies delivered intranasally for enhanced therapeutic efficacy.
MX2016007181A (en) 2016-10-28 Inhalable medicaments.
UA118192C2 (en) 2018-12-10 ANTI-VIRUS PHARMACEUTICAL COMPOSITION
MX2018015969A (en) 2019-06-10 Surfactant formulations for inhalation.
MX2015011624A (en) 2015-12-17 Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles.
MX2015009891A (en) 2016-03-08 Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy.
MX2023011674A (en) 2023-10-18 FORMULATIONS OF SURFACTANTS FOR INHALATION.
WO2013166430A3 (en) 2015-07-02 Delivery of gaseous imaging contrast agent
MX2020006634A (en) 2021-01-15 Surfactant formulations for inhalation.
MY171853A (en) 2019-11-05 Sphingomyelin-containing supplement
MX2017004633A (en) 2017-10-04 Formulations containing tiotropium, amino acid and acid and methods thereof.

Legal Events

Date Code Title Description
2018-03-22 FG Grant or registration